Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cemiplimab & Non-small-cell lung cancer (NSCLC), cemiplimab is FDA approved as first-line monotherapy for advanced/metastatic Non-small-cell lung cancer (NSCLC) in patients with high PD-L1 expression (≥50%). This approval was based on the EMPOWER-Lung 1 trial, which demonstrated significant improvement in overall survival compared to chemotherapy. EMA has also authorized cemiplimab for similar indications: first-line treatment of advanced Non-small-cell lung ca…